Drugs / CD19/CD22-CAR-transduced T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05442515 | Dec 2022 → Jul 2027 expected | precursor B-cell acute lymphoblastic leukemia | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/CD22-CAR-transduced T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05442515 ↗ |
| Modality | Cell therapy | “new type of CAR T-cell that is targeting both CD19 and CD22 at the same time” NCT05442515 ↗ |